Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Nutricharge - A complete training guide ~ 9711572735

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
540 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Oct 22, 2011

visit - http://www.facebook.com/prosumers - " The RCM Business School "

Ipca Laboratories Limited is a fully backward integrated, Indian pharmaceutical company with a strong thrust on exports. We are the largest manufacturers of few APIs which we produce right from the basic stage. More than half of our formulations business is backed by our own APIs.

APIs and Formulations are produced at world-class manufacturing facilities. These facilities have been approved by leading drug regulatory authorities - US FDA, MHRA UK, TGA Australia, MCC South Africa, WHO Geneva, HPFB Canada, PMDA Japan, WHO Geneva, KFDA Korea, EDQM and LAGeSO Berlin MOH.

Today, we are therapy leaders in antimalarials and rheumatoid arthritis in the Indian market, with a fast expanding presence in international market as well. We have brand leadership in 4-5 therapeutic areas, for both Formulations and APIs. Four of our major branded Formulations are ranked among top 300 brands of India and we have emerged as one among the top exporters of APIs in the world.

We are one of the biggest manufacturers in the world of APIs, to name a few - Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic), Pyrantel Salts (Anthelmintic), Hydroxy Chloroquine Sulphate (NSAID), Metoprolol Tartrate & Succinate (Antihypertensives). Ipca is also one of the largest suppliers of these APIs and their intermediates world over.

Our top 10 formulation brands are Zerodol (Aceclofenac & Combinations), Lariago (Chloroquine), HCQS (Hydroxychloroquine), Perinorm (Metoclopramide), Rapither (Artemotil), Tenoric (Chlorthalidone + Atenolol), Lumerax (Artemether + Lumefantrine), Etova (Etodolac), Malirid (Primaquine) and Folitrax (Methotrexate).

With operations in over 110 countries across the globe, exports and domestic business account for approximate equal contribution of the company's income.
Forbes, a leading US business magazine, selected Ipca in 2003, 2004, 2005 and 2007 among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. Amongst several other Indian companies, only few Indian Pharmaceutical companies featured in the said Forbes list. Ipca happens to be one of them.

Ipca has been awarded as "Among the 100 Best Companies to Work in India" during the survey conducted for 'India's Best Companies to Work For-2010'. This survey was conducted by Great Places to Work-India in joint collaboration with The Economic Times.

Financials
Company's net income for the financial year ended 31st March 2010 was Rs. 1559 crores and Net profit was Rs. 209 crores. Export sales accounted for 52% of Company's income.

We have set off in start of 2011, an initiative to promote 'Go Green, Save Environment'. This campaign is not only for Ipcaites, but for the whole world. We join you all, who are striving for this cause and to make this drive happen.

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more